Argano et al 8. Weber KT, Sun Y, Guarda E, et al. Myocardial fibrosis in hypertensive disease: An overview of potential regulatory mechanism. Eur Heart J 1995; 16 (Suppl C): 24-8. 9. Olsen MH, Christensen MK, Wachtell K, et al. Markers of collagen synthesis is related to blood pressure and vas- cular hypertrophy: A LIFE substudy. J Hum Hypert 2005; 19: 301-7. 10. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann DH. Identification of functional angiotensin II receptors on rat cardiac fibroblast. Circulation 1993; 88: 2849-61. 11. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen me- tabolism in cultured adult rat cardiac fibroblasts: Re- sponse to angiotensin II and aldosterone. J Mol Cell Car- diol 1994; 26: 809-20. 12. Dostal DE. Regulation of cardiac collagen: Angiotensin and cross talk with local growth factors. Hypertension 2001; 37: 841-4. 13. Lavie CJ, Ventura HO, Messerli FH. Regression of in- creased left ventricular mass by antihypertensives. Drugs 1991; 42: 945-61. 14. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ for the VA Cooperative Study Group on Antihypertensive Agents: Effect of single drug therapy on reduction of left ventricular mass in mid to moderate hypertension. Comparison of six antihyperten- sive agents. Circulation 1997; 95: 2007-14. 15. Klingbeil AU, Schneider MP, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treat- ment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6. 16. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regres- sion of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93. 17. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Ubago JLM. Losartan-dependent regression of myocar- dial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-7. 18. Devereux RC, Daholf B, Gerdts E, et al. Regression of hy- pertensive left ventricular hypertrophy by losartan com- pared with atenolol. Circulation 2004; 110: 1456-62. 19. Daholf B, Pennet K, Hansson L. Reversal of left ventricu- lar hypertrophy in hypertensive patients - a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95- 100. 20. Raasch W, Johren O, Schwartz S, Gieselberg A, Domini- ak P. Combined blockade of AT1-receptors and ACE syn- ergistically potentiates antihypertensive effects in SHR. J Hypertens 2004; 22: 611-8. 21. Suzuki H, Kanno YK, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on re- gression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dyal 2004; 8: 320-7. 22. Altman DG, Schultz KF, Moher D, et al for the CONSORT group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Int Med 2001; 134: 663-94. 23. de Simone G, Daniels SR, Devereux RB, et al. Left ven- tricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-60. 24. Licata G, Scaglione R, Corrao S, et al. Heredity and obe- sity associated hypertension. Impact of hormonal char- acteristics and left ventricular mass. J Hypertens 1995; 13: 611-8. 25. Yoshida J, Yamamoto K, Mano T, et al. AT1 receptor blocker added to ACE inhibitor provides benefits at ad- vanced stage of hypertensive diastolic heart failure. Hy- pertension 2004; 43: 686-91. 26. Parrinello G, Licata A, Colomba D, et al. Left ventricular filling abnormlaities and obesity-associated hyperten- sion: Relationship with overproduction of circulating transforming growth factor β1. J Hum Hypertens 2005; 19: 543-50. 27. Lonn E, Yusuf S, Jha P, et al. Emerging role of an- giotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-69. 28. Strawn WB, Dean RH, Ferrario CM. Novel mechanism linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000; 1: 11-7. 29. Navalkar S, Parthasarathy S, Santanam M, Khan BV. Irebesartan, an angiotensin type I receptor inhibitor, reg- ulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-4. 30. Pfeffer MA, Swedeberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart diseases: The CHARM-overall programme. Lancet 2003; 362: 759-66. 31. Mckelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in conges- tive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot Study. Circu- lation 1999; 100: 1056-64. 32. Yamamoto K, Masuyama T, Sakata Y, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002;55: 76-82. 33. Weber KT. Extracellular matrix remodelling in heart fail- ure: A role for de novo angiotensin II generation. Circula- tion 1997; 96: 4065-82. 34. Kim S, Yoshiyama M, Izumi Y, et al. Effects of combina- tion of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103: 148-54. 47